D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC gynaecological cancer co-operative group study
| Autor: | R Rosso, Aj. Lacave, F. Duffaud, K. J. Roozendaal, Jp. Guastalla, Nina Einhorn, Salvatore Tumolo, N. van der Vange, Pierre Kerbrat, Martine Piccart, M Namer, Wt. Huinink, Phb Willemse, M. Nooij, Mel Van der Burg, Jb. Vermorken, Taw. Splinter, Jaques Wils, G. Favalli, Ignace Vergote |
|---|---|
| Přispěvatelé: | Faculteit Medische Wetenschappen/UMCG |
| Jazyk: | angličtina |
| Rok vydání: | 2001 |
| Předmět: |
Cancer Research
medicine.medical_treatment Drug Resistance Salvage therapy Platinum Compounds THERAPY Pharmacology (medical) Aged 80 and over Ovarian Neoplasms Triptorelin Pamoate hormonal therapy Goserelin Triptorelin Middle Aged Survival Rate AGONIST Treatment Outcome ovarian cancer Oncology Hormonal therapy GROWTH Female medicine.drug Adult EXPRESSION medicine.medical_specialty Antineoplastic Agents Hormonal Urology GOSERELIN BINDING-SITES luteinizing hormone-releasing hormone medicine Humans Adverse effect Survival rate Aged Neoplasm Staging Pharmacology Gynecology Salvage Therapy Chemotherapy HORMONE-RELEASING HORMONE RECEPTOR business.industry Carcinoma GNRH-ANALOG medicine.disease Drug Evaluation business Ovarian cancer |
| Zdroj: | Anti-Cancer Drugs, 12(2), 159-162. LIPPINCOTT WILLIAMS & WILKINS Anticancer drugs |
| ISSN: | 0959-4973 |
| Popis: | Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl(R)). Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 and 28 followed by 4-weekly injections until tumor progression. No objective responses were observed. Eleven out of 68 evaluable patients (16%) had stable disease. The median progression-free survival was 5 months in patients with disease stabilization and 2 months for all evaluable patients. The median survival for patients with disease stabilization was 17 months, whereas for all patients it was 4 months. The treatment was well tolerated; the only reported adverse events were incidental hot flushes. This study showed that the LHRH agonist Triptorelin has only modest efficacy in patients pretreated with platinum-containing chemotherapy. [(C) 2001 Lippincott Williams & Wilkins.]. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|